Most Read Articles
29 Nov 2017
Rapid onset opioids may allow for more effective treatment of breakthrough cancer pain as their pharmacokinetic profile closely mimics the pain’s time course
Christina Lau, 22 Oct 2015
A 21-gene expression assay can identify patients with early-stage breast cancer who can skip adjuvant chemotherapy without facing an increased risk of recurrence at 5 years.
Elvira Manzano, 13 Sep 2017
Tisagenlecleucel, now US FDA approved, has made history as the first ever chimeric antigen receptor (CAR) T-cell therapy for B-cell precursor acute lymphoblastic leukaemia (ALL) – a breakthrough that has the potential to transform treatment for blood cancers that have not responded to standard therapies.
Naomi Adam, 01 Apr 2014

Colorectal cancer (CRC) is one of the most common cancers worldwide and its incidence is rising among Asians. Long-term survival outcomes are poor for CRC because patients often remain undiagnosed until the disease has reached an advanced stage. Panitumumab, a human IgG2 monoclonal antibody with high binding affinity for epidermal growth factor receptors, has shown encouraging results in the treatment of metastatic CRC (mCRC).

Genetic testing vital for lung cancer diagnosis, management

Dr Joslyn Ngu
04 Dec 2017

Genetic testing has changed the landscape of lung cancer and every patient needs to undergo testing, says a specialist.

Testing allows for the determination of actionable genetic alterations in lung cancer and is vital as it allows better treatment, said clinical oncologist Dr Tho Lye Mun. Research has found that patients with an oncogenic driver mutation who were given targeted therapy had better survival rate than those who did not receive targeted therapy and patients without an oncogenic driver. [JAMA 2014;311(19):1998–2006]

With the advancement in genetic testing, diagnosing lung cancer now involves an additional step. Besides conventional diagnosis using morphological or basic immunohistochemical features, for example to differentiate small cell lung cancer versus non-small cell lung carcinoma (NSCLC), identifying actionable genetic alterations such as EGFR, ALK , ROS-1 and PDL-1 should also be part of routine lung cancer diagnosis, said Tho.

The ability to classify patients in a more precise manner allows for more appropriate therapeutic strategy and for patients to receive the maximum effect of molecularly targeted drugs or immunotherapy. 

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
29 Nov 2017
Rapid onset opioids may allow for more effective treatment of breakthrough cancer pain as their pharmacokinetic profile closely mimics the pain’s time course
Christina Lau, 22 Oct 2015
A 21-gene expression assay can identify patients with early-stage breast cancer who can skip adjuvant chemotherapy without facing an increased risk of recurrence at 5 years.
Elvira Manzano, 13 Sep 2017
Tisagenlecleucel, now US FDA approved, has made history as the first ever chimeric antigen receptor (CAR) T-cell therapy for B-cell precursor acute lymphoblastic leukaemia (ALL) – a breakthrough that has the potential to transform treatment for blood cancers that have not responded to standard therapies.
Naomi Adam, 01 Apr 2014

Colorectal cancer (CRC) is one of the most common cancers worldwide and its incidence is rising among Asians. Long-term survival outcomes are poor for CRC because patients often remain undiagnosed until the disease has reached an advanced stage. Panitumumab, a human IgG2 monoclonal antibody with high binding affinity for epidermal growth factor receptors, has shown encouraging results in the treatment of metastatic CRC (mCRC).